Prostate-specific antigen: problems in analysis.
We have compared an "in-house" Tenovus Institute prostate-specific antigen (PSA) assay with four different commercial kits (ELSA-PSA, IRMA-Count PSA, PROS-CHECK PSA and TANDEM-R PSA) that are available in the UK. There was only good correlation and linear regression parameters between the in-house assay and one of the kit methods. The difference in values for the same sample ranged from 2 to 100-fold. These discrepancies are due, in part, to the specificity of the polyclonal and monoclonal antibodies used in the procedures and the differing "hook effects" caused by the binding capacity of the antibody pairs in the immunometric assays. Discrepancies will, however, result from the differing potencies of the standards used for the calibration curves. This data highlights the urgency for the introduction of an internationally accepted reference standard for PSA.
Turkes
A
A
Tenovus Institute for Cancer Research, University of Wales College of Medicine, Heath Park, Cardiff, U.K.
Nott
J P
JP
Griffiths
K
K
D000951:Antigens, Neoplasm / Q000032:analysis*; D006801:Humans; D007118:Immunoassay / Q000592:standards*; D008297:Male; D017430:Prostate-Specific Antigen; D011471:Prostatic Neoplasms / Q000276:immunology*; D012015:Reference Standards
D000951:Antigens, Neoplasm; D017430:Prostate-Specific Antigen